Latest Headlines from Nourish | The Nourish Mission

Blood biomarker prompts new CTE diagnosis hopes

What's happened

Recent studies have identified a blood biomarker, eMTBR-tau243, linked to chronic traumatic encephalopathy (CTE). While not yet a definitive test, findings suggest elevated levels in those with advanced CTE and may guide future monitoring and trials. Early-stage detection remains unresolved.

What's behind the headline?

Brief

  • New blood biomarker for CTE could enable living-diagnosis if validated.
  • Findings show elevated eMTBR-tau243 in some advanced CTE cases, not early-stage detection.
  • Results published in JAMA Neurology; cautions remain about overlap with other tauopathies.

Why it matters

This could shift how at-risk individuals are monitored and how trials are designed, potentially enabling earlier interventions once validated.

How we got here

CTE has been diagnosed posthumously via brain tissue analysis. Researchers from Washington University in St. Louis report that a tau fragment, eMTBR-tau243, is elevated in blood of some with advanced CTE, aligning with Alzheimer’s pathology in some cases. Larger studies are needed to validate a blood test as a living-diagnosis tool.

Our analysis

According to The New York Times, researchers report that two related tau markers are linked to CTE and may lead to a blood test; AP News notes initial findings require larger studies; The Guardian highlights that the biomarker could distinguish advanced CTE but not early-stage disease. All sources stress need for validation and context within overlapping tauopathies.

Go deeper

  • Could this biomarker become a standard screen for athletes and veterans?
  • What are the next steps in validating a living-diagnosis test for CTE?
  • How might this influence ongoing sports-safety protocols?

More on these topics


Latest Headlines from Nourish | The Nourish Mission